

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4, Opp. PCI, Ankleshwar – 393 002, Gujarat, India Tel : (02646) 220774 Fax : (02646) 251291 Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square, M. A. Road, Andheri (West), Mumbai – 400 058, India. Tel : (91-22) 26701050/1/2 Fax : (91-22) 26701053 E: contact@samratpharmachem.in

May 26, 2020

To, Department of Corporate Services, BSE Limited 25th Floor, P J Towers, Dalal Street, Mumbai - 400 001.

Dear Sir,

Sub: Reconciliation of Share Capital Audit f.t.q.e. 31/03/2020

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are forwarding herewith a Certificate issued by Practicing Company Secretary after conducting Reconciliation of Share Capital Audit for the quarter ended March 31, 2020.

Thanking you,

Yours faithfully, For Samrat Pharmachem Limited

Rajesh Mehta Executive Director

CS Dr. Aqueel A. Mulla

B.Com., L.L.M., F.C.S., A.C.I.S. (U.K.)., D.I.T., PhD

A. A. MULLA & ASSOCIATES Company Secretaries

A/603, Dhamm Seva CHS, (Deluxe Building), Opp. Kurla Railway Station, Kurla (East), Mumbai-24 M: 9892237418 Email: aqueelmulla@gmail.com

May 26, 2020

The Board of Directors, M/s. Samrat Pharmachem Limited Plot No. A2/3445, GIDC, Phase 4, Ankleshwar – 393 002, <u>Gujarat</u>.

Dear Sir,

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are enclosing herewith a Certificate issued by us after conducting Reconciliation of Share Capital Audit for the quarter ended **31st March, 2020**, as required under the said circular.

Please find the same in order & forward a copy of the same to the respective stock exchanges.

Yours faithfully, For A.A. Mulla & Associates Company Secretaries

Aqueel A. Mulla Proprietor

UDIN: F002973B000271164

Reconciliation of Share Capital Audit Report

(As per Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018).

Sr. No	Particulars	Details					
1.	For Quarter Ended	31 st March, 2020					
2.	ISIN	INE103E01016					
3.	Face Value	Rs. 10					
4.	Name of the Company	Samrat Pharmachem Limi	ted				
5.	Registered Office Address	Plot No. A2/3445,					
		GIDC, Phase 4,					
		Ankleshwar – 393 002,					
		Gujarat.					
6.	Correspondence Address	701/702, Business Square,	,				
		M. A. Road,					
		Andheri (West),					
		Mumbai – 400 058.					
7.	Tel No. & Fax No.	Tel : (022) 26701050					
	T 1 1 1	Fax : (022) 26701053					
8.	Email Address	contact@samratpharmachem.in					
	Website	www.samratpharmachem.com					
9.	Names of the stock exchanges where the company's securities are listed.	Mumbai					
10.	Issued Capital	No. of shares % of total issued capital					
		30,89,700	100.00 %				
11.	Listed Capital (Exchange Wise)						
	As per company records	30,89,700 100.00 %					
	 It is same for all the exchanges 						
12.	Held in dematerialized form in CDSL	4,06,514	13.16 %				
13.	Held in dematerialized form in NSDL	23,18,076 75.02 %					
14.	Physical	3,65,110 11.82 %					
15.	Total No. of shares (12+13+14)	30,89,700	100.00 %				
16.	Reasons for difference if any, between (10&11), (10&15), (11&15)	Nil					

17. Certifying the details of changes in share capital during the quarter under consideration as per table below:

Particulars ***	No. of shares	Applied / Not applied for listing	Listed on stock exchanges (specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Appr. Pending for SE (Specify Names)
Nil	Nil	Nil	Nil	Nil	Nil	Nil

*** Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify)

18.	Registrar of members is updated (Yes/No)	Yes
	If not, updated upto which date	Not Applicable

19. Reference of previous quarter with regards to excess de-materialised shares, if any.

20. Has the Company resolved the matter mentioned in Point No. 19 above in the current quarter ? If not, reason why ?

21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay :

Total No. of demat requests	No. of requests	No. of shares	Reason for delay
Confirmed after 21 days	0	0	-
Pending for more than 21 days	0	0	-

22.	Name, Tel No., Fax No. & Membership	Name	:	Mr. Sandeep Umashankar Prajapti
	No. of the Compliance Officer of the Co.	Tel No.	:	(91) 9867228874
		Fax No.	:	-
		Membership	:	ACS-57823
		No.		
		Email	:	contact@samratpharmachem.in

23.	Name, Address, Tel No. & Fax No., Regn	Name	:	A. A. Mulla & Associates
	No. of the Certifying CA/CS			Company Secretaries
		Address	:	A/603, Dhamm Seva CHS, (Deluxe
				Building), Opp. Kurla Railway
				Station, Kurla (E), Mumbai-400 024
		Membership	:	FCS 2973 CP 3237
		Tel No.	:	9892237418
		Fax No.		:-
		Email		aqueelmulla@gmail.com

24.	Appointment of common agency for share registry work	Name Address	Link Intime India Pvt Ltd C-101, 247 Park, L. B. S. Marg, Vikhroli (West), Mumbai – 400 083, Maharashtra.
		Tel No. Fax No. Email Kind Attn	(022) 49186000 (022) 49186060 rnt.helpdesk@linkintime.co.in Ms. Shweta Poojari

25. Any other detail that the CA/CS may like to provide (eg BIFR Company, de-listing from SE, etc)

For A. A. Mulla & Associates Company Secretaries

Aqueel A Mulla Proprietor C.P. No. 3237 CS No. 2973 UDIN: F002973B000271164

Date : May 26, 2020 Place : Mumbai